Virtu Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Virtu Financial’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20,738	Closed	-$1.42M	–	1996
2024 Q2	$1.42M	Buy	+20,738	New	+$1.44M	0.1%	207
2024 Q1	–	Sell	-7,623	Closed	-$546K	–	2241
2023 Q4	$546K	Buy	+7,623	New	+$439K	0.04%	382
2022 Q2	–	Sell	-17,143	Closed	-$1.05M	–	2183
2022 Q1	$1.05M	Buy	+17,143	New	+$890K	0.08%	213
2021 Q3	–	Sell	-9,780	Closed	-$399K	–	2062
2021 Q2	$399K	Buy	+9,780	New	+$362K	0.04%	581
2018 Q2	–	Sell	-18,538	Closed	-$390K	–	2591
2018 Q1	$390K	Buy	+18,538	New	+$361K	0.02%	856
2017 Q4	–	Sell	-91,437	Closed	-$1.44M	–	3126
2017 Q3	$1.44M	Buy	+91,437	New	+$1.34M	0.07%	286

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtu Financial's ITCI Position: Q3 2024 in Review

Virtu Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 20,738 shares — an estimated $1.42M sold.

Virtu Financial first reported a position in ITCI in Q3 2017 and held it in 6 quarters. The position peaked at $1.44M in Q3 2017. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Virtu Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Virtu Financial sold 20,738 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $1.42M.
Virtu Financial first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 6 quarters.
Virtu Financial's Intra-Cellular Therapies Inc. position peaked at $1.44M in Q3 2017.
354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Virtu Financial's 13F filing for Q3 2024, filed 20 Nov 2024.